During the debate about the planned statutory healthcare reform, Vice Chairman Stefanie Stoff-Ahnis of the GKV-Spitzenverband warned against allowing the savings generated by the pharmaceutical industry to fall short. Stating to the “Rheinische Post” that pharmaceuticals represent the second largest cost block in statutory health insurance, following hospitals, she added that the pharmaceutical industry is profiting immensely from this. She found it baffling that politicians intended to reduce the contributions from the pharmaceutical sector used to stabilize mandatory health insurance contribution rates, especially when compared to the proposals put forth by the Health Finance Commission.
According to GKV data, expenditures for medicines have soared by 118 percent between 2012 and 2025, reaching approximately 59 billion euros. Stoff-Ahnis emphasized that escalating medicine costs have long presented a massive challenge to the solidarity system. She argued that the reform currently being planned functions as a subsidy program for the pharmaceutical industry. If politicians fail to establish effective rules to control rising drug costs, the resulting higher health insurance contributions will ultimately be borne by insured persons and employers.
In this context, Stoff-Ahnis stressed the necessity of introducing a so-called dynamic manufacturer rebate, a measure that has faced significant resistance from the pharmaceutical industry. She described this dynamic manufacturer deduction as a “safety net” for contributors against increasing financial burdens. According to her, weakening this safety net means accepting continued rises in health insurance contributions. However, she clarified that the dynamic manufacturer rebate allows the pharmaceutical industry to maintain growing revenues while simultaneously preventing the overwhelming of insured persons and employers, who would otherwise be forced to shoulder the costs through their contributions.
